Vimizim Voucher A Result Of BioMarin’s Late Request, FDA Flexibility
Sponsors of rare pediatric disease treatments should be buoyed by news that FDA’s Office of Orphan Products Development liberally interpreted the FDASIA language that requires priority review vouchers be given only when an indication is limited to a pediatric population.
You may also be interested in...
US FDA program's new 2020 sunset could create a bolus of designation requests to ensure they can still get a voucher if it ends.
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.
FDA clearance of the Morquio A syndrome treatment provides some insight into how the agency is implementing the 2012 priority review voucher program aimed at incentivizing development of treatments for rare pediatric diseases.